Best of ASCO - 2014 Annual Meeting

 

Welcome

Neoadjuvant Therapy

Breast Cancer—Local/Regional/Adjuvant

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A longitudinal monitoring of left ventricular ejection fraction (LVEF) during reduced dosing anthracycline based chemotherapy in patients with breast cancer.

Yazan Numan

e12666

A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).

Emanuela Risi

570

Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.

Xavier Pivot

e12631

Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution experience.

Chad Glisch

e12662

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.

Saranya Chumsri

577

Association between HER2 positivity by HER2/CEP17 ratio and response to neoadjuvant HER2 targeted therapy.

Katherine Cynthia Rappazzo

e12632

Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.

Laura Spring

576

Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).

Tejal Amar Patel

581

Change in 21-gene recurrence score (RS) (Oncotype DX) after exposure to neoadjuvant endocrine therapy.

Talal Hilal

e12650

Clinical and biological features and response to preoperative chemotherapy in Russian women with breast cancer stage T1-3N0-1 according to genetic status.

Irina Vladimirovna Kolyadina

e12651

Correlation of near-infrared spectral tomography (NIRST) with residual cancer burden (RCB) for prognostic assessment subsequent to neoadjuvant chemotherapy (NAC) in breast cancer.

Erica Bernhardt

e12655

De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.

Valentina Guarneri

507

Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab.

Tamara Diaz-Redondo

e12634

DNA methylation as an epigenetic signature predictive of response to neodjuvant treatment in TNBC patients.

Begona Pineda

e12658

Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial.

Jose Bines

575

Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).

Lajos Pusztai

586

Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).

Emilio Alba

592

Effect of a combination of pertuzumab, trastuzumab, and weekly paclitaxel on pCR rates and side-effect profile as a neoadjuvant treatment regimen for HER2-positive breast cancer.

Niraj K. Gupta

e12652

Effect of carboplatin on pathologic complete remission rate and hematotoxicity incidence in neoadjuvant treatment of triple-negative breast cancer: A meta-analysis.

Hong-Fei Gao

e12638

Effect of neoadjuvant chemotherapy and recombinant tumor necrosis factor -thymosin –α 1 (TNF-T) on overall survival in patients with triple negative breast cancer (TNBC).

Liubov Yu Vladimirova

e12625

Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab.

Hans-Christian Kolberg

583

Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.

Melinda L. Telli

519

From PCR to miRNA profiling: Where is the true?

Paola Fuso

e12665

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Aleix Prat

509

Immune profiling of BRCA-mutated breast cancers.

Jeremy Meyer Force

585

Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.

Xiaotong Li

578

Immune response induced by preoperative chemotherapy in breast cancer: Role of peripheral natural killer (pNK) cell activity, tumor-infiltrating lymphocytes (TILs), and tumor microenvironment factors (TMEFs).

Ryungsa Kim

e12644

Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.

Oleg Gluz

573

Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST).

Clinton Yam

593

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

Nadia Harbeck

572

Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC).

Alison Laws

584

Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes.

Reva K Basho

588

InFlo: A systems biology framework to discover molecular mechanisms underlying response to therapy.

Salendra Singh

e12635

Institutional practice patterns for the use of neoadjuvant systemic therapy for breast cancer: A retrospective analysis.

Lara Zibdawi

e12637

Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer.

Emilio Alba

579

Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.

Sandra M. Swain

580

Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis.

Sherko Kummel

569

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).

Peter Schmid

TPS602

Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.

Christian F. Singer

589

Longterm survival benefit of neoadjuvant liposomal doxorubicin, docetaxel, and trastuzumab in HER2-overexpressing breast cancer: A retrospective and multicenter analysis.

Christine Brunner

e12653

Morbid obesity is related with adverse outcomes in triple negative breast cancer: A single institution experience.

Zeeshan Ali Jawa

e12663

Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.

Volker Moebus

568

Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+).

Jennifer Keating Litton

508

Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice.

Semir Beslija

e12661

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with HER2pos operable breast cancer treated with neo-adjuvant trastuzumab-containing chemotherapy.

Deirdre Kelly

594

NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.

Mark Basik

TPS604

NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).

Eleftherios P. Mamounas

TPS601

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

Charles E. Geyer

TPS603

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.

Jean Abraham

TPS605

Pathologic response to neoadjuvant therapy with nab-paclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.

Juan David Cardenas

e12660

Pathological complete response in basal subtype tumors to predict improved distant metastasis free survival in the NBRST trial.

Pat W. Whitworth

590

PerTe: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer patients—Efficacy and safety of pertuzumab in “real life" setting.

Daniela Cianniello

e12654

Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC).

Justin Stebbing

591

Platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): A systematic review and meta-analysis of randomized controlled trials (RCTs).

Francesca Poggio

595

Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS).

Stacy L. Moulder

518

Predicting neo-adjuvant chemotherapy response from pre-treatment breast MRI using machine learning and HER2 status.

Nathaniel Braman

582

Predicting pathological complete response (pCR) to neoadjuvant trastuzumab in patients with breast cancer using HER2 mass spectrometry.

Elisa Gasparini

e12643

Predictive value of neutrophil subtypes in response to neoadjuvant therapy in breast cancer patients.

Linxiaoxi Ma

e12642

Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).

Stephen James Luen

571

Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study.

Marika Cinausero

e12629

Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

Sibylle Loibl

104

Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.

Jeremy Force

e12641

Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL.

William Fraser Symmans

520

Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.

Carsten Denkert

574

Survival outcomes for polish women younger than age 40 years receiving trastuzumab for HER2-positive early breast cancer: A National population-based observational study.

Beata Jagielska

e12659

TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.

Roisin M. Connolly

511

The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice.

Irina Vladimirovna Kolyadina

e12656

The efficacy of preoperative metronomic therapy (MT) in luminal A locally advanced breast cancer.

Viacheslav Chubenko

e12664

The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.

Nina Prabha Tamirisa

587

Treatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes.

Ashley Pariser

e12630

Tumor-infiltrating lymphocytes and serum anti-p53 autoantibody in HER2-positive breast cancer treated with neoadjuvant chemotherapy.

Eriko Tokunaga

e12648

Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis.

Hee Jun Choi

e12640